A loophole allowing patent term extensions in Australia for certain Swiss-style claims has been closed

by FPA Patent Attorneys

FPA Patent Attorneys

The Australian Administrative Appeals Tribunal opened the door for patent term extensions based on a Swiss-form claim which enlarged the scope of applications of patent term extensions considerably. Recently, the Full Federal Court has reversed that decision.

Patent term extensions continue to be available for product claims and claims to processes of preparing a product that use recombinant DNA technology. However, other method and Swiss-form claims cannot support a patent term extension. Purpose-limited product claims are yet to be considered in this context.

Patent term Extensions

Patent term extension is available in Australia for patents covering pharmaceutical products that are registered on the Australian Register of Therapeutic Goods where the registration, and consequently sale, of the pharmaceutical product occurs more than 5 years after filing of the patent. One of the requirements for patent term extension in Australia is that either:

  1. a 'pharmaceutical substance per se…in substance fall within the scope of the claim or claims” of the relevant patent; or
  2. a 'pharmaceutical substance when produced by a process that involves the use of recombinant DNA technology…in substance fall within the scope of the claim or claims' of the relevant patent.

Option 1 has been judicially considered and determined to allow the extension of product claims but not method claims because a pharmaceutical substance per se does not in substance fall within the scope of a method claim. Option 2 had little judicial consideration prior to this series of cases.

Swiss-form claims and use of recombinant DNA technology

The present case involved the product adalimumab, which is prepared using recombinant DNA technology. There were several patents of interest all of which included exclusively “Swiss-form” claims. Attorneys commonly use the term “Swiss-form claim” to refer to claims of the following structure “use of compound [X] in the manufacture of a medicament for [a new therapeutic use]”. In Australia, Swiss-form claims are for methods of making medicaments which are purpose limited not methods of medical treatment as they were understood in Europe (see our related articles here for further information on the construction of Swiss-form claims and here for information on infringement of Swiss-form claims). Therefore, while the claims were for processes of preparing a pharmaceutical product using recombinant DNA technology, the claims also required that the product was for a specific therapeutic use.

Earlier decisions

The Patent Office found that the Swiss-form claims were characterised by a therapeutic use and therefore the pharmaceutical product prepared using recombinant DNA technology did not in substance fall within the scope of the Swiss-form claims. This decision was overturned on appeal at the Administrative Appeals Tribunal (AAT), where it was reasoned that the removal of the phrase “per se” from option 2 above meant that the option was not limited to product claims alone. The AAT decision indicated that it was enough if one of the features of the claim was the preparation of a pharmaceutical product using recombinant DNA technology and found that a request for patent term extension is not disqualified because the relevant claims are in the Swiss-form claim style. In the view of some commentators, the AAT decision had significant impact because it had the potential to apply to method claims and significantly extend the number of patents for which a patent term extension was available where a product was produced by recombinant DNA technology.

This decision

The Full Federal Court disagreed with the AAT. The Full Federal Court found that, as a pharmaceutical substance is a product, the patent term extension provisions are concerned with inventions that are products, not inventions that are methods or processes. The court cited the comments in Prejay Holdings that:

It is not enough that the substance appears in a claim in combination with other integers or as part of the description of a method (or process) that is the subject of a claim. The policy adopted in s 70 was to confine extensions to patents that claim invention of the substance itself.

The only exception is where a process involves recombinant DNA technology but that exception is limited to claims for the pharmaceutical substance so produced and not extended to other methods or processes involving the substance. The Court considered that the Swiss-form claims were not directed to adalimumab produced by recombinant DNA technology but were directed to different subject matter because of the aspect of the claims referring to the therapeutic use of adalimumab. Consequently, the pharmaceutical substance prepared by recombinant DNA technology did not in substance fall within the scope of the Swiss-form claims.

Status of patent term extension in Australia

Patent term extension continues to be available for product claims for a pharmaceutical substance per se. Product and process claims can support a patent term extension for a pharmaceutical substance produced using recombinant DNA technology so long as the process steps are limited to the preparation of the pharmaceutical substance using recombinant DNA technology. However, Swiss-form claims cannot be used to support patent term extension and claims for methods of use of a product, such as methods of medical treatment, also cannot support a patent term extension. There has been little judicial consideration of purpose-limited product claims in Australia so it is not yet clear whether these will be considered product or method claims in this context. That said, under current practice the Patent Office will construe purpose-limited product claims as method claims and refuse to grant patent term extension of such claims until there is judicial consideration of this issue.



[1] Subsection 70(2) of the Patents Act 1990.

[2] AbbVie Biotechnology Ltd (2015) 115 IPR 398 (Patent Office decision).

[3] Re AbbVie Biotechnology Ltd v Commissioner of Patents [2016] AATA 682 (AAT decision).

[4] Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129 at [49] (This decision).

[5] Prejay Holdings Ltd v Commissioner of Patents (2003) 57 IRP 424 at [24] (Prejay Holdings).

[6] Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129 at [55] (This decision).

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© FPA Patent Attorneys | Attorney Advertising

Written by:

FPA Patent Attorneys

FPA Patent Attorneys on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.